Triplet Therapy for Multiple Myeloma

May 23, 2013
Philip L. McCarthy, MD

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.

Clinical Pearls

Triplet therapies are often a combination of a novel drug (an IMiD or proteasome inhibitor) with two other agents or an IMiD and proteasome inhibitor with steroids. McCarthy says that triplet therapy is becoming a part of the gold standard for upfront myeloma treatment.

  • The current thinking is moving away from doublet therapy and towards triplet therapy for myeloma
  • Common triplet therapy regimens include:
    • lenalidomide + bortezomib + dexamethasone
    • cyclophosphamide + lenalidomide + dexamethasone
    • cyclophosphamide + bortezomib + dexamethasone
  • Triplet therapy is becoming a part of the gold standard for upfront myeloma treatment